Introduction: NSCLC is the leading cause for cancer-related deaths worldwide. New therapeutic targets are needed, as development of resistance to current treatment, such as platinum-based chemotherapy, is inevitable. The purpose of this study was to determine the functional relevance and therapeutic potential of cell division cycle associated 3 protein (CDCA3) in NSCLC.
Methods:
The expression of CDCA3 in squamous and nonsquamous NSCLC was investigated by using bioinformatics, Western blot analysis of matched tumor and normal tissue, and immunohistochemistry of a tissue microarray. The function of CDCA3 in NSCLC was determined by using several in vitro assays with small interfering RNA depleting CDCA3 in a panel of three immortalized human bronchial epithelial cell (HBEC) lines and seven NSCLC cell lines.
Results: In this study, cell division cycle associated 3 gene (CDCA3) transcripts were identified as highly increased in NSCLC versus in nonmalignant tissue, with high levels of CDCA3 being associated with poor patient prognosis. CDCA3 protein was also increased in NSCLC tissue and expression was limited to tumor cells. CDCA3 expression was similarly increased in a panel of NSCLC cell lines compared with in three HBEC lines. Although depletion of CDCA3 in the HBEC lines did not affect cellular proliferation, depletion of CDCA3 expression markedly reduced the proliferation of all NSCLC cell lines. CDCA3 depletion caused a defective G2/M-phase cell cycle progression, upregulation of p21 independent of p53, and induction of cellular senescence.
Conclusions:
Our findings highlight CDCA3 as a prognostic factor and potential novel therapeutic target in NSCLC through inhibition of tumor growth and promotion of tumor senescence.
Introduction
Lung cancer is the most common cancer and the leading cause of cancer-related deaths, accounting for more than 1.5 million deaths worldwide in 2014. [1] [2] [3] NSCLC is the most frequently diagnosed type of lung cancer, accounting for approximately 80% of cases. NSCLC is broadly subdivided into adenocarcinoma (ADC) and squamous cell carcinoma (SCC) on the basis of cell differentiation. Although early surgical resection of the primary tumor remains the best option for cure for NSCLC, most patients present with locally advanced or metastatic disease. Currently, the most effective therapy to achieve objective tumor shrinkage in the first-line treatment of metastatic disease is platinum-based chemotherapy. Although NSCLC is initially often responsive to chemotherapy, relapse and resistance to treatment is a major therapeutic problem. 4 Moreover, despite the introduction of surgical treatment options and improved combinational and targeted therapies, the global 5-year survival rate remains poor at 15%. 1 Identifying potential therapeutic targets is critical to the development of effective intervention strategies in lung cancer. A recent approach has centered on targeting the cell cycle to exploit and block the sustained proliferative capacity of cancer cells. Progression through the phases of the cell cycle relies on a complex network of proteins. Agents inhibiting proteins in this network, such as the U.S. Food and Drug Agency-approved palbociclib (which targets cyclin dependent kinase 4/cyclin dependent kinase 6), have shown great promise in breast cancer. 5 Other cyclin dependent kinase 4 and cyclin dependent kinase 6 inhibitors are currently in phase II and III clinical trials in lung cancer. 6, 7 Indeed, combination of agents targeting multiple cell cycle mediators may be necessary to achieve an improved clinical response.
Cell division cycle associated protein-3 (CDCA3), also known as trigger of mitosis entry 1, is reported to modulate cell cycle progression. CDCA3 functions as part of a SKP1-Cullin-RING-F-box (SCF) ubiquitin ligase (E3) complex to degrade the endogenous cell cycle inhibitor WEE1 G2 checkpoint kinase (WEE1), thereby modulating the cell cycle. 8, 9 CDCA3 levels are also regulated through the cell cycle by transcription and protein degradation during the G1 phase of the cell cycle. 8, 10 A role for CDCA3 in disease is also emerging with up-regulated expression noted in liver cancer, 11 oral SCC (OSCC) tissue, 12 and prostate cancer cells. 13 However, little else is known about CDCA3 in human cancers or whether this protein may prove useful clinically. Here we have examined the role of CDCA3 in NSCLC. Our data demonstrate that upregulation of CDCA3 expression is a common feature of NSCLC. We demonstrate that depletion of CDCA3 results in cell cycle defects with cells entering senescence, suggesting that CDCA3 may be a promising target for the treatment of lung cancer.
Materials and Methods

Antibodies and Reagents
Anti-CDCA3 antibody (HPA026587) and anti-p53 clone D07 were purchased from SigmaAldrich (Castle Hill, NSW, Australia). Anti-Actin and anti-p21 antibodies were purchased from Cell Signaling Technology (Genesearch, Gold Coast, Australia 
Western Blot Analyses
Western blot analysis on equal amounts of whole cell lysates was performed as previously described. 15 
qRT-PCR
Quantitative real-time polymerase chain reaction (qRT-PCR) was performed as described previously.
16 CDCA3 transcript levels (forward primer GGACCCTGAGACTCCCA GAT and reverse primer GCCGCTTACCCTGTCGTAG) were normalized to 7SL transcript levels (forward primer ATCGGGTGTCCGCACTAAGTT and reverse primer CAGCACGGGAGTTTTGACCT) by using the comparative C T method.
Immunofluorescence and High-Content Microscopy
Immunofluorescence was performed as previously described. 15 Images were collected on an InCell Analyzer 2200 high-content microscopy imaging system (GE Healthcare Life Sciences, Parramatta, Australia). Images were assessed with InCell Investigator software, version 1.6 (GE Healthcare Life Sciences). A minimum of 1000 cells were quantified per condition.
Apoptosis Assay and Cell Cycle Analysis
Viable and apoptotic cells were determined with the Annexin V-FITC apoptosis kit according to the manufacturers protocol (Promega, Alexandria, Australia). Briefly, all cell lines were enzymatically lifted and resuspended (at 1 Â 10 6 cells/mL) in binding buffer containing 488-conjugated anti-annexin (1:40 dilution). After a 20-minute incubation, cells were washed and stained with propidium iodide (1 mg/mL). Cells were assessed by using a Gallios flow cytometer (Beckman Coulter, Lane Cove, Australia) and data were analyzed with FlowJo X software (FlowJo, LLC, Ashland, OR).
To assess cell cycle distribution, cells were enzymatically lifted and fixed with 70% ethanol. After incubation at -20 C for at least 30 minutes, cells were stained with propidium iodide in PBS containing RNaseA (0.5 mg/mL) for 1 hour. Cells were assessed by using a Gallios flow cytometer (Beckman Coulter) and data were analyzed with FloJo X software.
Senescence Assays
Staining and quantification of the expression of senescence-associated b-galactosidase (SA-b-gal) in cells was performed as described previously. 17 
Cell Proliferation Assay
For all cell lines, 2.5 Â 10 3 cells were seeded into clear-walled 96-well plates and four regions per well were imaged every 2 hours over a period of 80 hours by using the Incucyte Zoom (Essen BioScience, Ann Arbor, MI). Image analysis was conducted with the Incucyte Zoom software package.
Bioinformatics and Statistical Analysis
CDCA3 transcript levels were determined by bioinformatics analysis of three independent microarray data sets (GSE19188, 18 GSE32863, 19 and GSE31210 20 ) comparing nonmalignant and cancer tissue. Distributions of log 2 median-centered signal intensities were presented as scatter plots. Statistical significance between groups was assessed with an unpaired t test. Survival analysis was performed with the online analysis tool Kaplan-Meier Plotter (http://kmplot.com/analysis/ index.php?p¼service&cancer¼lung). 21 Overall survival of cases stratified into high or low CDCA3 expression according to median gene expression was assessed in microarray data sets from the Cancer Biomedical Informatics Grid, the Gene Expression Omnibus, and The Cancer Genome Atlas. Groups were compared by Kaplan-Meier plots and the hazard ratio (HR) with 95% confidence intervals (CIs), and log-rank p values were calculated by using GraphPad Prism (GraphPad Software, La Jolla, CA).
Association of clinicopathological features and CDCA3 staining scores was assessed by using the chi-square test. Biological results are presented as the mean plus or minus SD of at least three independent experiments. Statistical significance was assessed by using a paired Student's t test in all experiments, and p values of 0.05 or less were considered significant.
Results
CDCA3 Transcripts Are Increased in NSCLC and Correlate with Poor Outcome
To determine the potential role of CDCA3 in NSCLC, expression of CDCA3 transcripts was evaluated by bioinformatics analysis of three available NSCLC microarray data sets. [18] [19] [20] Within these data sets, the expression of CDCA3 was correlated with available patient data.
As shown in Figure 1A, (Fig. 1B) . Also, although there was no statistical difference in CDCA3 mRNA expression in normal tissue from nonsmokers versus in normal tissue from smokers, there was a difference in CDCA3 mRNA expression in cancerous tissue from nonsmokers versus in cancerous tissue from smokers (p ¼ 0.02), suggesting that the etiology of the tumor may be important ( Supplementary Fig. 1A ).
Increased expression of CDCA3 was also observed in each of the three NSCLC subtypes, namely, ADC (log 2 Fig. 1B ) and lower in EGFR-mutant tumors ( Supplementary Fig. 1C ).
As shown in Figure 1D , univariate Kaplan-Meier analysis of 1145 cases indicated that patients with NSCLC with high CDCA3 expression had a poorer outcome than those with lower CDCA3 expression (HR ¼ 2.54, CI: 2.12 -3.05, log rank p < 1 -16 ). To confirm the prognostic value of CDCA3, patient data were stratified for stage and histologic type. High CDCA3 expression remained prognostic for patient outcome when all patients with stage I and II disease were combined (HR ¼ 2.68, CI: 2.14 -3.31, log rank p < 1 -16 [ Supplementary Fig. 1D] ) and for patients with stage I disease alone (HR ¼ 3.87, CI: 2.77 -4.76, log rank p < 1 -16 [ Supplementary Fig. 1E] ). Although less statistically significant, CDCA3 expression also remained prognostic for outcome within stage II patients (HR ¼ 1.56, CI: 1.08 -2.26, log rank p ¼ 0.018 [ Supplementary Fig. 1F] ). Within the ADC histologic type of NSCLC, high CDCA3 expression was similarly prognostic for patient outcome (HR ¼ 2.78, CI: 2.16 -3.45, log rank p < 1 -16 [ Supplementary Fig. 1G ]). However, unlike in patients with ADC, CDCA3 expression had no prognostic value in patients with SCC (HR ¼ 1.09, CI: 0.86 -1.38, not significant [ Supplementary Fig. 1H]) .
Multivariate Cox regression survival analysis was also performed to determine whether CDCA3 expression remained an independent prognostic factor for outcome of patients with NSCLC when the parameters sex and smoking were considered. Notably, high CDCA3 expression remained an independent prognostic factor (HR ¼ 1.85, CI: 1.5 -2.29, log rank p < 0.0001) for outcome of patients with NSCLC (Table 1) . Within the multivariate analysis for CDCA3 expression, although the parameter smoker remained an independent prognostic factor for patient outcome (p ¼ 0.0194), the parameter sex was not significant (p ¼ 0.0711).
CDCA3 Protein Is Up-regulated in Tissue from
Patients with NSCLC and In Vitro CDCA3 protein expression was assessed in TMAs of ADC and SCC NSCLC by using immunohistochemistry, with the TMAs containing 74 and 84 evaluable cases respectively. Of the 74 ADC NSCLC cases, 60 (81.1%) exhibited CDCA3 expression to varying intensity ( Fig. 2A) . Similarly, 62% of 84 cases of SCC NSCLC exhibited varied CDCA3 expression (Fig. 2B) . Within the CDCA3-expressing ADC tumors, 5.4% of cases exhibited high-intensity staining whereas 21.6% and 54.1% exhibited moderate and weak staining intensity, respectively. For SCC NSCLC tumors, CDCA3 expression was highest in 3.6% of cases, moderate in 21.4% of cases, and weak in 36.9% of cases. Of the evaluable ADC cases and SCC cases, CDCA3 was primarily detected within the tumor regions and not in the stroma or nonneoplastic tissue (Fig. 2C) . Cytoplasmic staining of CDCA3 was the predominant staining pattern detected in cancer cells. In 13% of ADC cases and 7% of SCC cases, a proportion of cells also exhibited perinuclear and nuclear localization.
CDCA3 expression quantified from TMA scores and stratified by median score was correlated with available clinicopathological parameters. As shown in Table 2 , higher CDCA3 expression (patients with scores greater than the median score of 20) was associated with ADC (p ¼ 0.0006) relative to SCC. Higher CDCA3 expression was also correlated with higher tumor grade (p ¼ 0.0027), with a statistically significant association of higher CDCA3 expression with positive surgical resection margins (p ¼ 0.02). CDCA3 expression was not found to be correlated with surgical stage, patient age, sex, or smoking status. Kaplan-Meier analysis of the evaluable ADC and SCC cases for CDCA3 staining did not reveal any correlation between overall survival and CDCA3 protein expression.
We next evaluated the expression of CDCA3 in tumor and matched normal tissue from five ADC NSCLC tumors and five SCC NSCLC tumors by Western blot analysis. As shown in Figure 2D , CDCA3 was detected as a prominent band at approximately 35 kDa. Increased levels of CDCA3 were detected in three of five ADC tissue samples and four of five SCC tissue samples versus in their matched normal tissue samples, confirming CDCA3 overexpression in NSCLC.
To determine whether CDCA3 mRNA and protein expression was comparatively up-regulated in our NSCLC cell lines versus in immortalized epithelial cells, qRT-PCR and Western blot analysis were performed. Our qRT-PCR analysis showed that CDCA3 transcript was low in all three HBEC cell lines yet increased in all of the NSCLC cell lines tested (Fig. 2E) . Interestingly, the transcript levels for the cell lines representative of ADC (A549 and H2228), LCC (H460), and SCC (SKMES, EBC-1, HTB-182, and CRL-5889) followed a trend similar to that observed in the bioinformatic analysis (Fig. 1C) , with the H460 LCC line showing the highest expression. Western blot analysis was performed for CDCA3 and p53 expression in whole cell lysates from the same panel of cell lines analyzed by qRT-PCR. p53 expression was comparable between the HBEC cells and A549, H460, and SKMES-1 cells (Fig. 2F) . Truncated p53 was detected in H2228 and CRL-5889 cells and not detected in EBC-1 and HTB-182 cells, which is consistent with the Catalogue of Somatic Mutations in Cancer database. 22 CDCA3 protein was largely increased in NSCLC cell lines versus in the HBEC cells, with the exception of the EBC-1 and CRL-5889 cells (Fig. 2F) . There was no apparent correlation between CDCA3 and p53 protein levels across cell lines. Taken together, the in vitro and clinical data indicate that CDCA3 is frequently upregulated in NSCLC.
CDCA3 Mediates NSCLC Cell Proliferation
As CDCA3 transcript and protein levels are increased in NSCLC and predict poor patient outcome, we sought to examine the function of this protein in a range of in vitro cell assays. The panel of lung and NSCLC cell lines that were evaluated in Figure 2E and F were used to examine the effect of CDCA3 depletion on cell growth. We utilized two distinct siRNAs (siCDCA3-1 and siCDCA3-2) targeting the CDCA3 transcript or mocktreated the cells (small interfering control). Depletion of CDCA3 in each of the cell lines was confirmed by Western blot analysis of total cell lysates, with the siRNAs siCDCA3-1 and siCDCA3-2 reducing protein levels in all cell lines by approximately 85% and approximately 93%, respectively (Fig. 3A) . Depletion of CDCA3 in each of the HBEC cell lines resulted in no change in cell growth (Fig. 3B-D) , whereas depletion of CDCA3 (with either siRNA) in the NSCLC cell lines resulted in marked a retardation of cell growth (Fig. 3E-K) .
To determine whether the marked suppression of NSCLC cell line proliferation was due to an increase in cell death, we performed staining for propidium iodide and annexin V. Cells staining positive for both dyes have entered apoptosis. Across the HBEC4 cells and all NSCLC cell lines, depletion of CDCA3 did not affect the proportion of apoptotic cells (Supplementary Fig. 2 ). These data indicate that cell death is not a factor impacting cellular proliferation.
CDCA3 Depletion Results in Defective G2/M Cell Cycle Progression Leading to Senescence
Given the profound impact of CDCA3 depletion on cell proliferation and the reported role of this protein in cell cycle regulation, 8 we tested whether CDCA3 depletion affected cell cycle progression and cellular senescence in NSCLC cell lines. To investigate cell cycle defects, the DNA content of propidium iodide-stained asynchronous control or CDCA3-depleted cells was assessed by flow cytometry. Although CDCA3 depletion did not affect cell cycle progression in any of the HBEC cell lines, depletion of CDCA3 in each of the NSCLC cell lines affected the gross DNA content profile, exhibiting a marked increase in the portion of cells in the G2/M phase of the cell cycle (Fig. 4A) . Across each of the NSCLC cell lines, a minimum approximately twofold increase in the proportion of cells in the G2/M phase was noted, with H2228, H460, and SKMES-1 cell lines exhibiting a greater than threefold increase in the proportion of cells in G2/M phase (Fig. 4B ). This observation in NSCLC cell lines is consistent with the documented function of CDCA3 in modulating levels of WEE1 protein, which functions to prevent premature mitotic entry. Concurrent with the defective G2/M progression and a marked impact on cellular proliferation, cells depleted of CDCA3 were larger than control cells. We quantified the impact of CDCA3 depletion on cell size by using flow cytometry and analyzing the forward scatter plots. As shown in Figure 5A , NSCLC cells depleted of CDCA3 were larger than the control cells, with mean fluorescence intensity values approximately fourfold greater than those of the control cells. An enlarged cellular morphologic pattern is consistent with cells that have entered senescence. To assess whether CDCA3 depletion induced NSCLC cell lines to enter senescence, we stained for SA-b-gal activity. In all NSCLC cell lines, but not in any of the immortalized epithelial HBEC cell lines, CDCA3 depletion resulted in an increased proportion of cells staining positive for SA-b-gal (Fig. 5B) . Depletion of CDCA3 from A549, H460, SKMES-1, CRL-5889, and HTB-182 cells resulted in a greater than fivefold increase in SA-b-gal positivity whereas depletion in H2228 and EBC-1 cells yielded a modest approximately twofold increase in SA-b-gal positivity (Fig. 5C) .
To address how CDCA3 depletion induces cellular senescence, high-content immunofluorescence was performed to examine the expression of p21. Senescence is triggered in response to stresses signaled by two main pathways: activation of p16 or p21. [23] [24] [25] The Catalogue of Somatic Mutations in Cancer database and other reports indicate that the p16 minigene pathway is disrupted in most of the NSCLC cell lines used in this study either by homozygous deletion (A549, H2228, H460, and HTB-182) or mutation (CRL-5889). 22, [26] [27] [28] [29] Accordingly, p21 was the only marker examined. As shown in Figure 6A , depletion of CDCA3 induced an increase in nuclear immunofluorescent staining of p21 in all cell lines with the exception of the three HBEC cell lines. Quantification of the immunofluorescence with high-content microscopy demonstrated a greater than threefold increase in nuclear p21 in all NSCLC cell lines with the exception of A549 cells, which demonstrated an approximately twofold increase in p21 protein (Fig. 6B) . The levels of p21 were unchanged in each of the three immortalized epithelial HBEC cell lines depleted of CDCA3 (Fig. 6B) . As p21 is a p53-responsive gene, we sought to determine whether p53 was similarly involved in the induction of senescence by staining for p53 in two of the wild-type (WT) p53-expressing cell lines: A549 and H460. As shown in Figure 6C and D, the levels and staining intensity of p53 remained unchanged in CDCA3-depleted cells compared with in control cells. These results suggest the potential involvement of p21 but not p53 in mediating cellular senescence in NSCLC cells depleted of CDCA3.
Discussion
In this study, we have demonstrated for the first time that CDCA3 has a key role in the proliferation and cell cycle progression of NSCLC cells. In patients with NSCLC, CDCA3 transcripts are upregulated in cancer versus in nonmalignant tissue and this increased expression correlates with a poorer overall survival. CDCA3 protein is expressed in 81.1% of ADC cases and 61.9% of SCC cases and not expressed in proximal nonmalignant tissue. Depletion of CDCA3 inhibits the growth of NSCLC cells in vitro through defective cell cycle progression and induction of senescence. Our results suggest that developing strategies to target CDCA3 might selectively inhibit NSCLC cell progression in most patients and preserve normal cells and structures. As such, CDCA3 is a novel prognostic factor and potential target for therapy in this disease.
In recent bioinformatics studies of microarray data sets from 163 tumor types identified a network of closely regulated genes that included CDCA3 with strong prognostic importance. 30 This bioinformatic analysis was confirmed by qRT-PCR demonstrating the upregulation of CDCA3 transcripts in breast, kidney, lung and ovarian cancers versus in normal tissue. Moreover, ectopic overexpression of CDCA3 in hepatoma cell lines enhanced cell proliferation but did not affect apoptosis. 30 The impact of modulating CDCA3 protein levels on cell proliferation and apoptosis is consistent with the results of our study. Although our bioinformatic analysis indicates that increased expression of CDCA3 is associated with poor patient outcome, we found no significant correlation between CDCA3 protein levels in patient samples and outcome in NSCLC. The TMA was, however, from a relatively small cohort of patients, and further studies focused, in particular, on molecularly characterized ADC tumors would be required to interrogate the prognostic relevance of this potential prognostic tumor marker.
We examined seven NSCLC cell lines to demonstrate the functional importance of CDCA3 in NSCLC cells. Depletion of CDCA3 in NSCLC cell lines led to defective cell cycle progression and induction of senescence, resulting in marked suppression of cell proliferation. This is in keeping with an earlier report demonstrating that CDCA3 expression was increased in OSCC. Depletion of the protein reduced the proliferation of two human oral cancer cell lines. 12 In the OSCC cell lines, CDCA3 depletion yielded a cell cycle arrest at the G1 phase with a concurrent increase in cyclin inhibitors and INK4 family members. 12 In contrast, we noted a defective cell cycle progression with an increased proportion of cells in the G2/M phase upon CDCA3 depletion in NSCLC cell lines. Our data are in line with the reported mechanistic role for CDCA3. CDCA3 functions as part of the SCF ubiquitin ligase complex to regulate mitotic entry by controlling the levels of WEE1 protein. 8 Nonetheless, it is possible that the molecular regulation of CDCA3 and the function of the protein may vary across malignancies of different origin.
Data from our panel of cell lines indicate that a key outcome of CDCA3 depletion is the induction of senescence. p16 and p53-p21 are key regulators of cellular senescence. [23] [24] [25] In our panel of cell lines, the p16 pathway is largely disrupted either by deletion (A549, H2228, H460, and HTB-182) or by mutation (CRL-5889). Of these cells, only two lines have WT p53 (A549 and H460), with the remainder of the cell lines harboring mutated full-length (SKMES-1) or truncated p53 (H2228 and CRL-5889) or deleted for p53 (EBC-1 and HTB-182 [ Fig. 2F]) . 22 Our results indicate that CDCA3 depletion can induce senescence in p16-or p53-deficient cell lines. This suggests that p16 and p53 do not play important roles in CDCA3 depletion-mediated senescence. We confirmed this in A549 and H460 cells (WT p53 and homozygous deletion of p16) by depleting CDCA3, and we were unable to observe an increase in cellular p53 levels ( Fig. 6C and D ). An increase in protein levels for the p53-responsive gene p21 was seen in all NSCLC cell lines tested, irrespective of the p53 status. Consistently, knockdown of regulator of cullins-1, a regulator of the SCF complex, also induces p21-dependent and p53-independent cell senescence to suppress the growth of liver cancer cells. 31 Whether cells depleted of CDCA3 induce senescence in a manner similar to regulator of cullins-1-depleted cells remains to be determined. Collectively, these findings suggest that p21, but not p53 or p16, is required to induce CDCA3 depletion-induced senescence.
In summary, our findings demonstrate that CDCA3 transcripts and protein are up-regulated versus normal tissue in most patients with NSCLC. CDCA3 is a potential prognostic factor in NSCLC. In NSCLC cell lines, CDCA3 is functionally important in mediating cancer cell proliferation. Depletion of the protein inhibits efficient cell cycle progression and mediates induction of senescence. These findings indicate that CDCA3 is a potential novel therapeutic target in NSCLC to inhibit tumor growth and promoting tumor senescence. Accordingly, induction of senescence is a promising approach in cancer therapy. 24, 25, 32, 33 Further work is required to define the molecular pathways that up-regulate CDCA3 and that those that are regulated by CDCA3 to enable development of novel anticancer therapies for NSCLC.
